Akèy › Kansè nan tete › Texas › Austin
Etid klinik pou Kansè nan tete nan Austin, TX
18 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Austin (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- New Experimental Therapeutics - NEXT Oncology, Austin
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- Next Oncology Austin, Austin
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- NEXT Oncology - Austin, Austin
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Texas Oncology, Austin
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- Texas Oncology Central/South, Austin
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Austin, Austin
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Texas Oncology - Central/South Texas, Austin
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Ap rekriteFaz 3
- Texas Oncology - Austin, Austin
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- Texas Oncology - Central / South Texas, Austin
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Ap rekriteFaz 1/2
- Texas Oncology - Central/South, Austin
Cancer Pain Management Using a Web-based Intervention
Ap rekrite
- The University of Texas at Austin, Austin
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Ap rekriteFaz 3
- Texas Oncology - Central South (Balcones Dr), Austin
- Texas Oncology - Central South (James Casey), Austin
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology Austin, Austin
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Elligo Health Research, Inc., Austin
Sample Collection for Ongoing Research and Product Evaluation Study
Ap rekriteEtid obsèvasyon
- Natera, Inc., Austin
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #4, Austin
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Ap rekriteEtid obsèvasyon
- Texas Oncology - Austin, Austin
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Ap rekriteFaz 2
- Texas Oncology PA (Austin), Austin
Etid Kansè nan tete nan lòt vil
- New York City, NY134 etid
- Houston, TX126 etid
- Boston, MA111 etid
- Nashville, TN80 etid
- Los Angeles, CA72 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Durham, NC63 etid
- Queens, NY63 etid
- Chicago, IL58 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Austin
- Kansè Poumon ki pa ti selil30 etid
- Kansè (tout kalite)20 etid
- Obèsite20 etid
- Kansè Metastatik19 etid
- Kansè kolorektal19 etid
- Ensifizyans kadyak18 etid
- Sipwa18 etid
- Kansè ovè17 etid
- Kansè Endomèt15 etid
- Kansè pwostat15 etid
- Depresyon14 etid
- Kansè tete negatif triple13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.